Publication Name	World Journal of Hepatology
Manuscript ID	90241
Country	United States

Received	2023-11-27 22:40
Peer-Review Started	2023-11-27 22:42
First Decision by Editorial Office Director	2024-01-05 03:21
Return for Revision	2024-01-05 03:59
Revised	2024-01-23 05:04
Publication Fee Transferred
Second Decision by Editor	2024-02-29 02:43
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-02-29 06:55
Articles in Press	2024-02-29 06:55
Edit the Manuscript by Language Editor	2024-02-22 14:10
Typeset the Manuscript	2024-03-11 02:34
Publish the Manuscript Online	2024-03-27 13:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents
Manuscript Source	Invited Manuscript
All Author List	Robert Lam and Joseph K Lim
ORCID	Author(s) ORCID Number Joseph K Lim http://orcid.org/0000-0003-1037-5773
Funding Agency and Grant Number
Corresponding Author	Joseph K Lim, MD, Professor, Section of Digestive Diseases, Yale University School of Medicine, Yale Liver Center, 333 Cedar Street, LMP 1080, New Haven, CT 06520, United States. joseph.lim@yale.edu
Key Words	Hepatitis B viru; Treatment; Clinical trials; RNA interference; Entry inhibitors; Core inhibitors; Immunomodulators
Core Tip	Novel investigational agents targeting functional cure [sustained hepatitis B surface antigen (HBsAg) loss and undetectable hepatitis B virus (HBV) DNA] are currently in clinical trial development. Herein we review key evidence from phases 2 and 3 trials defining the efficacy and safety profiles for key investigational agents, including core/capsid inhibitors, entry inhibitors, RNA interference (siRNA/ASO), HBsAg inhibitors, Toll-like receptor agonists, checkpoint inhibitors, and therapeutic vaccines.
Publish Date	2024-03-27 13:28
Citation	Lam R, Lim JK. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents. World J Hepatol 2024; 16 (3): 331-343
URL	https://www.wjgnet.com/1948-5182/full/v16/i3/331.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i3.331

Full Article (PDF)	WJH-16-331-with-cover.pdf
Manuscript File	90241_Auto_Edited-LJH_WangTQ-YJP.docx
Answering Reviewers	90241-Answering reviewers.pdf
Audio Core Tip	90241-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	90241-Conflict-of-interest statement.pdf
Copyright License Agreement	90241-Copyright license agreement.pdf
Peer-review Report	90241-Peer-review(s).pdf
Scientific Misconduct Check	90241-Bing-Liu JH-2.png
Scientific Misconduct Check	90241-CrossCheck.png
Scientific Editor Work List	90241-Scientific editor work list.pdf
CrossCheck Report	90241-CrossCheck report.pdf